<DOC>
	<DOCNO>NCT01820364</DOCNO>
	<brief_summary>The primary purpose Phase II CLGX818X2102 study assess anti-tumor activity LGX818 combination select agent .</brief_summary>
	<brief_title>LGX818 Combination With Agents ( MEK162 ; BKM120 ; LEE011 ; BGJ398 ; INC280 ) Advanced BRAF Melanoma</brief_title>
	<detailed_description>This phase II two part multi-center , open-label study . Part I : LGX818 single agent treatment progression Part II : Combination treatment LGX818 + MEK162 , BKM120 , BGJ398 , INC280 , LEE01 assess clinical efficacy , evaluate safety drug combination patient locally advance metastatic BRAF mutant melanoma relapse LGX818 , determine maximum tolerate dose combination ( establish previously ) . These drug combination select assign patient base documentation molecular resistance mechanism . Patients BRAF mutant melanoma treat LGX818 single agent study enrol directly Part II CLGX818X2102 relapse . Dose-escalations combination arm MTD establish base recommendation Bayesian logistic regression model guide escalation overdose control criterion . After careful evaluation slow enrollment BRAF-mutant melanoma treatment landscape , recruitment permanently halt 26-Jul-2014 . This recruitment halt consequence safety concern patient ongoing study continue treat per protocol .</detailed_description>
	<mesh_term>Melanoma</mesh_term>
	<criteria>locally advanced metastatic melanoma confirm BRAF V600 mutation patient naïve selective BRAF inhibitor fresh tumor biopsy baseline , patient agree mandatory biopsy time relapse life expectancy ≥ 3 month World Health Organization ( WHO ) Performance Status ≤ 2 . Previous treatment RAFinhibitor Symptomatic untreated leptomeningeal disease Symptomatic brain metastasis . Known acute chronic pancreatitis Clinically significant cardiac disease AST/SGOT ALT/SGPT &gt; 2.5 x ULN , &gt; 5 x ULN liver metastases present Impairment gastrointestinal ( GI ) function GI disease may significantly alter absorption oral interventional drug Previous concurrent malignancy . Other severe , acute , chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation Specific exclusion criterion treatment arm : LGX818/MEK162 : History current evidence retinal disease History Gilbert 's syndrome . LGX818/BKM120 : Patients diabetes mellitus require insulin treatment Patient mood disorder LGX818/BGJ398 : History and/or current evidence ectopic mineralization/ calcification Current evidence corneal disorder/ keratopathy Patients current evidence endocrine alteration calcium/phosphate homeostasis . History congenital long QT syndrome and/or hypokalaemia CTCAE Grade ≥ 3 and/or magnesium level clinically relevant low limit study entry . Ionized ( ) calcium ( Ca ) &gt; ULN Serum inorganic phosphorus ( Pi ) &gt; ULN LGX818/LEE011 History congenital long QT syndrome and/or hypokalaemia CTCAE Grade ≥ 3 and/or magnesium level clinically relevant low limit study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>open-label study</keyword>
	<keyword>BRAF inhibitor</keyword>
	<keyword>LGX818</keyword>
	<keyword>MEK1620</keyword>
	<keyword>MAPK1/2 inhibitor</keyword>
	<keyword>Pi3K inhibitor</keyword>
	<keyword>FGFR</keyword>
	<keyword>c-Met</keyword>
	<keyword>CDK4/6</keyword>
	<keyword>metastatic melanoma</keyword>
	<keyword>BRAF</keyword>
	<keyword>V600</keyword>
</DOC>